# A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies

> **NCT02013804** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 58 (actual)

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** MEDI0680 (AMP-514)

## Key facts

- **NCT ID:** NCT02013804
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-19
- **Primary completion:** 2017-05-18
- **Final completion:** 2017-05-18
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2017-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02013804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02013804, "A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02013804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*